MedPath

International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry

Active, not recruiting
Conditions
Stroke
Atrial Flutter
Patent Foramen Ovale
Atrial Fibrillation
Interventions
Device: PFO closure
Registration Number
NCT04738071
Lead Sponsor
Lawson Health Research Institute
Brief Summary

Patent foramen ovale (PFO) is a prevalent cause of ischemic stroke and transient ischemic attack (TIA) in young patients. Its role as a cause of cerebrovascular events in the older population is more controversial because of other competing causes are more frequent in the elderly. Recent randomized controlled trials (RCTs) have shown that PFO closure is associated with a 59% relative risk reduction in the risk of recurrent ischemic stroke. As such, the number of PFO closure procedures are expected to increase substantially in the upcoming years. Real world data (RWD) informing on the medical management, the risk of stroke recurrence, incident atrial fibrillation, and other outcomes in stroke patients with PFO, with and without PFO closure, will become crucial for understanding how results from RCTs are translated into clinical practice globally.

The IMPROVE (International Multicenter Patent foRamen OVale \& strokE) Registry is an observational, multicenter, international registry of men and women with an ischemic stroke or TIA. The aim is to enroll 8,800 patient-years at ≥50 sites in ≥20 countries.

The IMPROVE Registry will provide important information about the management and related outcomes of patients with ischemic stroke or TIA and PFO throughout different regions of the world and across a wide spectrum of healthcare systems.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
3730
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
SexPFO closureFemale and male patients
Stroke vs. TIAPFO closureIndex event: stroke vs. TIA
Age >60 years of agePFO closurePatients younger or oder than 6o years of age
Neurocardiology TeamsPFO closurePatients assessed by a neurocardiology team
World regionPFO closurePatients from different world regions: North America, Europe, Asia, Latin America
Primary Outcome Measures
NameTimeMethod
Recurrent strokeDuration of follow-up (minimum of 3 months)

Recurrent hemorrhagic or ischemic stroke

Secondary Outcome Measures
NameTimeMethod
Incident atrial fibrillationDuration of follow-up (minimum of 3 months)

New diagnosis of atrial fibrillation after the index date

Proportion of patients undergoing PFO closureWithin 12 months of the index diagnosis of PFO after the stroke or transient ischemic attack

Proportion of patients undergoing PFO closure

Trial Locations

Locations (1)

Heart & Brain Lab, Western University

🇨🇦

London, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath